At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 150 enrolled
Drug / intervention
Testosterone enanthate auto-injectorcombination
Likely dose
Testosterone enanthate auto-injector 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
In Brief
A Phase 3 clinical trial evaluating Testosterone enanthate auto-injector for Hypogonadism. Completed, enrolled 150 participants across 28 sites.
Detailed Summary
Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJul 2014
Primary CompletionFeb 2015
Study CompletionNov 2015
TodayJul 2026
First PostedJun 10, 2014
Enrollment StartJul 1, 2014
Primary CompletionFeb 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.1 years ago
Interventions
Testosterone enanthate auto-injectorcombination
Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels